# A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD

> **NCT06533553** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Areteia Therapeutics** · enrollment: 30 (estimated)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Dexpramipexole Dihydrochloride

## Key facts

- **NCT ID:** NCT06533553
- **Lead sponsor:** Areteia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-09
- **Primary completion:** 2025-10
- **Final completion:** 2025-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06533553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06533553, "A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06533553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*